Dianthus Therapeutics financials
$87.16−0.76%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $761.0K | $463.0K | $284.0K | $396.0K | $193.0K | $1.2M | $1.3M | $2.2M | $1.9M | $874.0K | $457.0K | $924.0K |
| Gross profit | $761.0K | $463.0K | $284.0K | $396.0K | $193.0K | $1.2M | $1.3M | $2.2M | $1.9M | $874.0K | $457.0K | $924.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$61.5M | -$46.5M | -$69.5M | -$40.3M | -$34.9M | -$33.2M | -$31.9M | -$29.9M | -$22.2M | -$17.8M | -$13.0M | -$15.8M |
| Net income | -$50.2M | -$40.8M | -$64.4M | -$36.8M | -$31.6M | -$29.5M | -$28.4M | -$25.2M | -$17.6M | -$13.7M | -$10.6M | -$14.8M |
| Net margin | −6598.6% | −8819.4% | −22687.3% | −9284.1% | −16388.1% | −2537.5% | −2144.8% | −1159.0% | −945.1% | −1573.0% | −2311.4% | −1597.7% |
| Diluted EPS | $-0.90 | $-0.85 | $-1.43 | $-0.97 | $-0.88 | $-0.82 | $-0.73 | $-0.74 | $-0.51 | $-0.54 | $-0.71 | $-3.78 |
| EBITDA | -$61.4M | -$46.5M | -$69.5M | -$40.3M | -$34.9M | -$33.1M | -$31.9M | -$29.9M | -$22.2M | -$17.8M | -$12.9M | -$15.7M |
| Operating cash flow | -$49.0M | -$28.9M | -$47.0M | -$30.6M | -$23.9M | -$27.6M | -$27.4M | -$21.3M | -$14.5M | -$14.9M | -$11.9M | -$10.0M |
| Free cash flow | -$49.2M | -$28.9M | -$47.1M | -$30.6M | -$23.9M | -$27.7M | -$27.5M | -$21.3M | -$14.5M | -$15.0M | -$11.9M | -$10.1M |
| Diluted shares | 56.0M | 48.0M | 45.1M | 37.8M | 35.8M | 35.8M | 39.1M | 34.2M | 34.2M | 25.7M | 15.0M | 3.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $110.5M | $627.7M | $51.1M | $56.0M | $13.2M | $10.1M |
| Short-term investments | $776.3M | $483.6M | $353.2M | $346.6M | $244.2M | $253.1M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.21B | $1.25B | $530.9M | $577.4M | $326.1M | $348.6M |
| Total liabilities | $41.2M | $45.6M | $37.5M | $31.0M | $23.0M | $20.0M |
| Shareholders' equity | $1.17B | $1.20B | $493.4M | $546.5M | $303.1M | $328.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology